Cases & Deals

Baxter Ventures invests in Ocular Therapeutix

Clients Baxter International Inc.

Jones Day advised Baxter Ventures in connection with its purchase of Series D-1 Convertible Preferred Stock in a private placement by Ocular Therapeutix, Inc., a developer of ophthalmic therapeutic products through use of its proprietary hydrogel technology.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.